Sign in

    Billal Jahangiri • Truist Securities

    Billal Jahangiri is a Research Analyst who served at Truist Securities from 2020 to 2025, focusing on the healthcare and biotechnology sectors. He actively covered public companies such as Coherus BioSciences and AbCellera Biologics, regularly participating in their quarterly earnings calls and providing investment insights. Jahangiri began his professional journey after earning an undergraduate degree from the University of Georgia in 2015, with prior career experience including roles at Centiva Capital LP before his tenure at Truist. He holds relevant industry credentials, including FINRA registration as required for equity research roles at registered broker-dealers.

    Billal Jahangiri's questions to Curis Inc (CRIS) leadership

    Billal Jahangiri's questions to Curis Inc (CRIS) leadership • Q3 2024

    Question

    Billal Jahangiri from Truist Securities inquired about the broader potential of emavusertib in high-risk MDS, asking about the prevalence of relevant mutations and the strategic rationale for pursuing a doublet combination before the VERONA study readout.

    Answer

    President and CEO James Dentzer responded that the MDS opportunity is exciting and a key focus. He noted that the company is exploring different dosing regimens and potential combinations, acknowledging that the VERONA study readout will be influential. He expressed anticipation for the upcoming data presentation at ASH, which will inform the strategy for 2025.

    Ask Fintool Equity Research AI